Filing Flows › Castle Biosciences (CSTL) › Q3 2026 › vs Q2 2026
Castle Biosciences (CSTL) Q3 2026 vs Q2 2026 (quarter over quarter)
Castle Biosciences's revenue fell $655K (-0.6%) from $104M in Q2 2026 to $103M in Q3 2026. The biggest changes: Dermatologic −$827K (-2%); Non-Dermatologic +$172K (+0.3%).
Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 11.9% | 6.3% | +5.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Non-Dermatologic | $55.0M | $54.8M | $172K | +0.3% |
| Dermatologic | $47.9M | $48.7M | −$827K | -2% |
| Revenue | $103M | $104M | −$655K | -0.6% |
| Net loss | $4.1M | $2.1M | $2.0M | +99% |
| Costs & expenses | $107M | $107M | $5K | 0% |
| Operating costs | $106M | $107M | −$994K | -0.9% |
| Interest & other, net | $1.1M | −$1.4M | $2.5M | — |
| Income tax | $298K | $370K | −$72K | -19% |
| Cost of revenue | $23.9M | $23.7M | $219K | +0.9% |
| Research & development | $15.8M | $14.5M | $1.3M | +9% |
| SG&A | $63.8M | $66.1M | −$2.3M | -4% |
| Other operating costs | $2.1M | $2.3M | −$147K | -7% |
| Operating cash sources | $23.8M | $17.3M | $6.6M | +38% |
| Depreciation & amortization | $4.2M | $4.1M | $109K | +3% |
| Share-based compensation | $11.2M | $11.6M | −$357K | -3% |
| Working capital & other | $8.4M | $1.6M | $6.8M | +426% |
| Net loss absorbed | $4.1M | $2.1M | $2.0M | +99% |
| Operating cash flow | $19.7M | $15.2M | $4.5M | +30% |
| Free cash flow (OCF − capex) | $12.2M | $6.6M | $5.7M | +87% |
| Capital expenditures | $7.5M | $8.7M | −$1.2M | -13% |
Questions
How much did Castle Biosciences's revenue grow quarter over quarter in Q3 2026?
Castle Biosciences's revenue fell $655K (-0.6%) from $104M in Q2 2026 to $103M in Q3 2026.
What drove Castle Biosciences's revenue change in Q3 2026?
Dermatologic −$827K (-2%); Non-Dermatologic +$172K (+0.3%).